Abstract
First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for patients with advanced non-small cell lung cancer who were selected on the basis of EGFR mutations have improved the progression-free survival with acceptable toxicity compared to standard chemotherapy. However, acquired resistance to EGFR-TKIs has been identified as an important clinical problem. Transformation to small cell lung cancer (SCLC) is a rare mechanism of resistance to EGFR-TKI therapy. We describe the case of a 61-year-old man who presented transformation from adenocarcinoma to SCLC as the manifestation of acquired resistance after EGFR-TKI treatment. He underwent chemotherapy with etoposide and cisplatin and achieved a complete response.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / genetics
-
Adenocarcinoma / pathology*
-
Adenocarcinoma of Lung
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Drug Resistance, Neoplasm*
-
ErbB Receptors / genetics*
-
Etoposide / administration & dosage
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology*
-
Male
-
Middle Aged
-
Mutation*
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Remission Induction
-
Small Cell Lung Carcinoma / drug therapy*
-
Small Cell Lung Carcinoma / genetics
Substances
-
Protein Kinase Inhibitors
-
Etoposide
-
EGFR protein, human
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Cisplatin